Glass Label/Claim Audit

Magnesium L Threonate Renal Impairment

Durable audit route for one claim-like target. This page shows source-use records, assessment rationale, active challenges, revisions, and graph edges tied to the same target identity.

evidence medium
Assessment Rationale

Renal impairment is included with provisional confidence because the record has direct section evidence but still needs endpoint-specific interpretation before it should be read as a strong clinical claim.

The assessment is anchored to the cited clinical guidance record rather than inferred from the compound name alone.

Evidence Reviewed

Sources considered for this assessment[1]

Guidance Scope
Endpoint
Renal Impairment
Context
Clinical Guidance
Does not mean
  • - Not a diagnosis or personalized medical decision
  • - Not a complete effect-size claim
  • - Not individualized medical guidance
Basis For Guidance
01Record supportMedium

The row has an explicit structured record and citation mapping.

02Endpoint directnessLow

The current seed evidence does not yet carry the same detailed endpoint interpretation as Taurine.

03CMS readinessMedium

The audit path is present; additional source interpretation can be added without changing the schema.

Supports this guidance
  • - structured record exists
  • - citation support is mapped to this row
Limits this guidance
  • - interpretation remains provisional
  • - effect size and population scope need fuller review
Disputable assumptions
  • - endpoint inference
  • - population generalization
  • - whether the row should be strengthened or narrowed
Source Use Records

Local evidence attached to this claim

MixedSafety ContextSafety Context5/5 quality fields

Magnesium status, sleep quality, and stress physiology

Reduced kidney function can impair magnesium clearance and increase risk from duplicate magnesium sources.

This source supports safety, monitoring, or interaction context for the safety profile.

Endpoint
Renal impairment
Population
Healthy adults or older adults
Dose / Exposure
1-2 g/day oral
Duration
4-12 weeks
Directness
Safety Context